Almost two years ago, the FDA approved Ledipasvir-Sofosbuvir (aka Harvoni) for pediatric patients 12-17 years of age with hepatitis C virus (HCV) infection. Now, a recent study (KF Murray, WF Balistreri, S Bansal et al. Hepatology 2018; 68: 2158-66) is likely to expedite approval for children ages 6-11 years of age.
In this open-label study with 92 patients, 88 had genotype 1, 89 received treatment with ledipasvir-sofosbuvir without ribavirin for 12 weeks, 97% were perinatally-infected, and 78% were treatment naive. The median age was 9 years. The dose (determined by intense pharmacokinetics) was 45 mg-200 mg (half the adult dosage). Two patients with genotype 3 HCV received ledipasvir-sofosbuvir for 24 weeks along with ribavirin.
- SVR12 was 99% (91/91). The single patient without SVR12 had relapsed 4 weeks after completing a 12 week treatment course.
- Ledipasvir-sofosbuvir was well-tolerated; the common adverse events reported were headache and pyrexia.
The authors note that while most children are considered to have mild symptoms or are asymptomatic, some progress to have significant fibrosis or cirrhosis, a small minority develop hepatocellular carcinoma, and HCV infection can impact both cognitive development and overall health.
My take: This study confirms that effectiveness of DAA therapy with ledipasvir/sofosbuvir in children as young as 6 years of age.
Related study: F Tucci et al. Hepatology 2018; 68: 2434-37. The authors report the successful treatment with ledipasvir/sofosbuvir of an infant with both SCID and HCV infection.
Related blog posts:
- New HCV Treatment Effective in Adolescents
- HCV Guidelines
- An “Ally” for Hep C Genotype 3
- A New Villain for Hepatitis C | gutsandgrowth
- Understanding HCV Treatment Failures with Sofusbuvir …
- Genotyping Still Matters for Hepatitis C (in 2018)
- Hepatitis C Infections Increasing Tied to Opioid Epidemic (in 2018)
- Opioid Epidemic Affecting Adolescent Hepatitis C Infections
- Heroin Epidemic Causing Surge in Hepatitis C Infections
- HCV now more deadly than HIV
- Hepatitis C : New and Newer Treatments
- Burden of Hepatitis B and Hepatitis C | gutsandgrowth
- Word of Caution with New Hepatitis C Medications | gutsandgrowth